Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how much revenue was received by the NHS from commercial clinical trial activity in each of the last five years.

We are unable to provide information on revenue received by the National Health Service from commercial clinical trial activity as this data is not routinely collected by the NHS.

Growth and investment from commercial clinical trial activity is a key priority for the Government. The Government is working to improve transparency of and reduce negotiation time for the full recovery of costs between NHS sites and commercial sponsors, through the National Contract Value Review (NCVR). NCVR employs the 2022/23 national tariff, encompassing investigation and intervention tariffs, procedure tariffs, and the NHS England Market Forces Factor.

Lord O’Shaughnessy’s report of his review of commercial clinical trials in the United Kingdom, published in May 2023, recommends measures to boost commercial trial activity. The government supports these recommendations in principle and will be publishing a full response to the review in the autumn.